JPWO2019241744A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019241744A5 JPWO2019241744A5 JP2021519529A JP2021519529A JPWO2019241744A5 JP WO2019241744 A5 JPWO2019241744 A5 JP WO2019241744A5 JP 2021519529 A JP2021519529 A JP 2021519529A JP 2021519529 A JP2021519529 A JP 2021519529A JP WO2019241744 A5 JPWO2019241744 A5 JP WO2019241744A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- pabra
- blocker
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685244P | 2018-06-14 | 2018-06-14 | |
| US62/685,244 | 2018-06-14 | ||
| US201862686654P | 2018-06-18 | 2018-06-18 | |
| US62/686,654 | 2018-06-18 | ||
| US201962825619P | 2019-03-28 | 2019-03-28 | |
| US62/825,619 | 2019-03-28 | ||
| PCT/US2019/037371 WO2019241744A1 (en) | 2018-06-14 | 2019-06-14 | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527712A JP2021527712A (ja) | 2021-10-14 |
| JPWO2019241744A5 true JPWO2019241744A5 (https=) | 2022-06-08 |
| JP2021527712A5 JP2021527712A5 (https=) | 2022-06-08 |
Family
ID=68842373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519529A Pending JP2021527712A (ja) | 2018-06-14 | 2019-06-14 | 神経系疾患および障害を、診断、監視、および治療するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210251559A1 (https=) |
| EP (1) | EP3806957A4 (https=) |
| JP (1) | JP2021527712A (https=) |
| AU (1) | AU2019287779A1 (https=) |
| CA (1) | CA3100697A1 (https=) |
| WO (1) | WO2019241744A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4076422A4 (en) * | 2019-12-18 | 2024-01-24 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| JP7734700B2 (ja) * | 2020-06-04 | 2025-09-05 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニストの形態及び組成物 |
| CN116801875A (zh) * | 2020-09-01 | 2023-09-22 | 库拉森疗法公司 | 用于改善神经疾病和病症的组合物和方法 |
| EP4208159A4 (en) * | 2020-09-01 | 2024-09-25 | Curasen Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE RELIEF OF NEUROLOGICAL CONDITIONS AND DISORDERS |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| US9492114B2 (en) * | 2004-06-18 | 2016-11-15 | Banner Health Systems, Inc. | Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease |
| US8758723B2 (en) * | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| JP6133790B2 (ja) * | 2011-02-18 | 2017-05-24 | ザ スクリプス リサーチ インスティテュート | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
| US9320724B2 (en) * | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| WO2014152529A2 (en) * | 2013-03-14 | 2014-09-25 | Georgetown University | Fmri biomarker of neurodegenerative disease |
| US9889087B2 (en) * | 2014-06-10 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
-
2019
- 2019-06-14 JP JP2021519529A patent/JP2021527712A/ja active Pending
- 2019-06-14 EP EP19819482.1A patent/EP3806957A4/en not_active Withdrawn
- 2019-06-14 AU AU2019287779A patent/AU2019287779A1/en not_active Abandoned
- 2019-06-14 US US16/972,985 patent/US20210251559A1/en not_active Abandoned
- 2019-06-14 WO PCT/US2019/037371 patent/WO2019241744A1/en not_active Ceased
- 2019-06-14 CA CA3100697A patent/CA3100697A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527712A5 (https=) | ||
| Kato et al. | Involvement of the frontotemporal lobe and limbic system in amyotrophic lateral sclerosis: as assessed by serial computed tomography and magnetic resonance imaging | |
| Vendette et al. | Brain perfusion anomalies in rapid eye movement sleep behavior disorder with mild cognitive impairment | |
| Varley et al. | Imaging neuroinflammation in Alzheimer's disease and other dementias: recent advances and future directions | |
| Yamamoto | Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background | |
| Barthel et al. | Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls | |
| Delano-Wood et al. | Posterior cingulum white matter disruption and its associations with verbal memory and stroke risk in mild cognitive impairment | |
| Mayberg et al. | Paralimbic hypoperfusion in unipolar depression | |
| Kuhl et al. | In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease | |
| Wada et al. | Abnormal functional connectivity in Alzheimer’s disease: intrahemispheric EEG coherence during rest and photic stimulation | |
| Vendette et al. | Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder | |
| Foster et al. | The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography | |
| Merschdorf et al. | Psychopathological symptoms of depression in Parkinson’s disease compared to major depression | |
| Navarro et al. | Frontal cerebral perfusion dysfunction in elderly late-onset major depression assessed by 99MTC-HMPAO SPECT | |
| André et al. | Rapid eye movement sleep, neurodegeneration, and amyloid deposition in aging | |
| JPWO2019241744A5 (https=) | ||
| JP2021527711A5 (https=) | ||
| Zhang et al. | Aberrant white matter microstructure in depressed patients with suicidality | |
| JPWO2021127210A5 (https=) | ||
| Hesse et al. | Regional serotonin transporter availability and depression are correlated in Wilson’s disease | |
| Salmon et al. | Anterior cingulate and motor network metabolic impairment in progressive supranuclear palsy | |
| Kincses et al. | The pattern of diffusion parameter changes in Alzheimer's disease, identified by means of linked independent component analysis | |
| Battistin et al. | Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine | |
| Brauer Boone et al. | Frontal lobe cognitive functions in aging: Methodologic considerations | |
| Inoue et al. | Electroencephalographic finding in idiopathic REM sleep behavior disorder |